ECHO 4 PWS: Orthopedics
When: Tuesday, December 17, 2024 at 5:00 PM EST
Where: Virtual/Zoom Video
This series is for healthcare providers only
PWSA | USA's - ECHO 4 PWS Healthcare Provider Series
PWSA | USA launched our new Healthcare Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to healthcare professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.
Our next healthcare ECHO topic will take place on Tuesday, December 17, 2024, at 5:00 p.m. EST and will focus on Orthopedics and PWS presented by Dr. Harold van Bosse, followed by a 20-minute case study on PWS.
PWSA | USA’s Healthcare Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.
While this ECHO series is only for healthcare providers to attend, recordings of the webinars are available for our PWS families to view HERE.
Scroll below to find more ECHO 4 PWS webinar opportunities.
Speaker
Harold van Bosse, MD
ECHO 4 PWS is Sponsored By
LEarn More about PWS Research
HERO Clinical Trial for ARD-101 Now Enrolling Open-Label Extension (OLE)
Earlier this year, Aardvark Therapeutics launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). All patients who have completed treatment on the AVK-101-301 study through Week 12/End of Treatment will have the option to join […]
Acadia Shares Results of Phase 3 Carbetocin Trial: Primary Endpoint Not Met
On Wednesday, September 24, 2025, Acadia Pharmaceuticals shared an update on their Phase 3 COMPASS PWS trial, which evaluated intranasal carbetocin (ACP-101) for hyperphagia (excessive hunger) in children and adults with Prader-Willi syndrome (PWS). The trial did not meet its primary endpoint of improving scores on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) from baseline […]
Aardvark Therapeutics HERO Trial: U.S. Sites Now Open
Aardvark Therapeutics recently launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). This randomized, double-blind, placebo-controlled trial is an important step toward identifying a potential new treatment option for the PWS community, and […]
Perry A. Zirkel has written more than 1,500 publications on various aspects of school law, with an emphasis on legal issues in special education. He writes a regular column for NAESP’s Principal magazine and NASP’s Communiqué newsletter, and he did so previously for Phi Delta Kappan and Teaching Exceptional Children.
Jennifer Bolander has been serving as a Special Education Specialist for PWSA (USA) since October of 2015. She is a graduate of John Carroll University and lives in Ohio with her husband Brad and daughters Kate (17), and Sophia (13) who was born with PWS.
Dr. Amy McTighe is the PWS Program Manager and Inpatient Teacher at the Center for Prader-Willi Syndrome at the Children’s Institute of Pittsburgh. She graduated from Duquesne University receiving her Bachelor’s and Master’s degree in Education with a focus on elementary education, special education, and language arts.
Evan has worked with the Prader-Willi Syndrome Association (USA) since 2007 primarily as a Crisis Intervention and Family Support Counselor. Evans works with parents and schools to foster strong collaborative relationships and appropriate educational environments for students with PWS.
Staci Zimmerman works for Prader-Willi Syndrome Association of Colorado as an Individualized Education Program (IEP) consultant. Staci collaborates with the PWS multi-disciplinary clinic at the Children’s Hospital in Denver supporting families and school districts around the United States with their child’s Individual Educational Plan.
Founded in 2001, SDLC is a non-profit legal services organization dedicated to protecting and advancing the legal rights of people with disabilities throughout the South. It partners with the Southern Poverty Law Center, Protection and Advocacy (P&A) programs, Legal Services Corporations (LSC) and disability organizations on major, systemic disability rights issues involving the Individuals with Disabilities Education Act (IDEA), Americans with Disabilities Act (ADA), and the federal Medicaid Act. Recently in November 2014, Jim retired.